Elite receives FDA nod for supplemental application for Hydromorphone
Elite Pharmaceuticals has received FDA approval for supplemental application for the manufacturing and packaging of Hydromorphone Hydrochloride USP 8mg.
The approval will allow the company to initiate the commercial manufacturing and packaging of the product for its sales.
The company's marketing partner will distribute the product as part of a multi-product distribution agreement.
Hydromorphone hydrochloride is a member of the opioid analgesic and antitussive class which is used primarily for pain relief or as a cough suppressant.
Related Insight
Suppliers Directory
Lonza Custom Manufacturing - Bioresearch Products, Development Services and Manufacturing for Functional and Active Ingredients
Lonza Custom Manufacturing offers the life sciences market a full range of bioresearch products, flexible development services and high-quality manufacturing for functional and active ingredients.
Production & Manufacturing > Manufacturing > Suppliers
Fujifilm Diosynth Biotechnologies - Biopharmaceutical Process Development and Manufacturing Services
Fujifilm Diosynth Biotechnologies is one of the world’s leading providers of contract process development and manufacturing services for the biopharmaceutical industry. Formed in April 2011 following the acquisition of the MSD BioManufacturing Network, the company has over 800 employees operating from two sites in Billingham, UK (formerly Avecia Biologics) and Research Triangle Park, North Carolina, USA (formerly Diosynth Biotechnology).
Production & Manufacturing > Manufacturing > Suppliers
Trigona – Synthesis Development and Kilogram Synthesis
Trigona oHG, a privately-held chemical company, is engaged in the synthesis, development and multi-kilogram manufacturing of chemical products.
Production & Manufacturing > Manufacturing > Suppliers
MHRA - The Medicines and Healthcare Products Regulatory Agency
The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency responsible for ensuring that medicines and medical devices work, and are acceptably safe.
Production & Manufacturing > Manufacturing > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Manufacturing Intelligence
Pharma News Special
Published by Shimadzu PBR
Production & Manufacturing > Manufacturing > White Papers
PEGylation - The Magic Wand
Published by IRIS Biotech
Production & Manufacturing > Manufacturing > White Papers
Robolux Multiway Multiport Diaphragm Valve
Published by Burkert Fluid Control Systems
Production & Manufacturing > Manufacturing > White Papers
Reduced Solvent Consumption and Operational Costs with Ultra High Speed Analysis
Published by Shimadzu PBR
Production & Manufacturing > Manufacturing > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.